UCLL is a leading partner (work package lead) in the EIT Higher Education Initiative project LEAPXR. The project offers UCLL an opportunity to combine their ambition to make innovation and entrepreneurship an integral part of applied higher education with a technology that has clear potential for healthcare education and practice.

Funded under Horizon Europe (HORIZON-HLTH-2024-CARE-14-01), running from 2025 to 2029, the THERESA PCP aims to launch a pre-commercial procurement process (PCP) based on the development of an environmentally sustainable on-site system to decontaminate hospital wastewater. Ziekenhuis aan de Stroom (ZAS) plays an important role in the project by contributing real-world insights from a large and diverse hospital network. Read more about the project in this testimonial.

The YoPA project, ‘a youth-centred preventive action approach towards co-created implementation of socially and physically activating environmental interventions’ obtained funding from Horizon Europe’s Health Cluster. The project addresses the multifaceted challenges of physical inactivity and health inequalities through a unique participatory approach. The project places teenagers between 12 and 18 years old in vulnerable situations at the forefront of the intervention process. The Institute of Tropical Medicine is a partner in the project and will conduct a Realist Evaluation to understand how youth co-creation contributes to improved adolescent health and well-being in four cities in Denmark, Netherlands, Nigeria and South Africa.  By integrating its results and sharing its approach in an open access Toolbox, ITM aims to contribute to fostering sustainable, youth-led solutions for healthier urban environments.

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.